High-dose rifampicin, moxifl oxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Common Terminology Criteria for Adverse Events

  2020cited by this paper
• E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs — Questions and Answers (R3) Guidance for Industry

  2017cited by this paper
• A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

  2016cited by this paper
• Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis.

  2016cited by this paper
• High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo

  2015cited by this paper
• Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

  2015cited by this paper
• Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.

  2015cited by this paper
• The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.

  2015cited by this paper
• Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

  2015cited by this paper
• The association between sterilizing activity and drug distribution into tuberculosis lesions

  2015cited by this paper
• A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

  2015cited by this paper
• Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

  2015cited by this paper
• The Molecular Bacterial Load Assay Replaces Solid Culture for Measuring Early Bactericidal Response to Antituberculosis Treatment

  2014cited by this paper
• Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

  2014cited by this paper
• Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media.

  2014cited by this paper
• Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

  2013cited by this paper
• Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

  2012cited by this paper
• Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

  2012cited by this paper
• Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

  2012cited by this paper
• The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

  2011cited by this paper
• Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review.

  2011cited by this paper
• Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

  2011cited by this paper
• Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

  2007cited by this paper
• Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

  2007cited by this paper
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis

  2003cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• Clinical Pharmacokinetics of Rifampicin

  1978cited by this paper

• Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment

  2025cites this paper
• Tuberculosis molecular bacterial load assay in the management of tuberculosis

  2024cites this paper
• Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

  2024cites this paper
• Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens

  2023cites this paper
• Recent advances in the treatment of tuberculosis.

  2023cites this paper
• Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study

  2023cites this paper
• Chitinase and indoleamine 2, 3-dioxygenase are prognostic biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis

  2023cites this paper
• Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania

  2023cites this paper
• Molecular Mechanisms of MmpL3 Function and Inhibition

  2023cites this paper
• Mycobacterium smegmatis: The Vanguard of Mycobacterial Research

  2023cites this paper
• Methodology and design of platform trials: a meta-epidemiological study

  2023cites this paper
• Current Prospects: Drug acting against resistant Tuberculosis

  2023cites this paper
• A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy

  2023cites this paper
• Hybrid Raman spectroscopy and artificial neural network algorithm discriminating mycobacterium bovis BCG and members of the order mycobacteriales

  2023cites this paper
• A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis

  2023cites this paper
• High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2)

  2023cites this paper
• Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.

  2023cites this paper
• Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

  2023cites this paper
• The TuberXpert project protocol: Towards a Clinical Decision Support System for therapeutic anti-tuberculosis medical drugs monitoring in Tanzania

  2023cites this paper
• Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database

  2023cites this paper
• Hybrid use of Raman spectroscopy and artificial neural networks to discriminate Mycobacterium bovis BCG and other Mycobacteriales

  2023cites this paper
• Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s

  2023cites this paper
• Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin

  2023cites this paper
• Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials

  2023cites this paper
• Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections

  2023cites this paper
• Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin

  2023cites this paper
• MDR Tuberculosis Treatment

  2022influential citation
• Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

  2022cites this paper
• The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis

  2022cites this paper
• Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies

  2022cites this paper
• Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse

  2022cites this paper
• Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

  2022cites this paper
• Degradation of Polymer-Drug Conjugate Nanoparticles Based on Lactic and Itaconic Acid

  2022cites this paper
• New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

  2022cites this paper
• Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial

  2022cites this paper
• A comparison of clinical development pathways to advance tuberculosis regimen development

  2022cites this paper
• Mutations in rv0678 confer low-level resistance to benzothiazinone DprE1 inhibitors in M. tuberculosis

  2022cites this paper
• Field Grand Challenge Frontiers in Antibiotics

  2022cites this paper
• High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis

  2022cites this paper
• Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

  2022cites this paper
• Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

  2022cites this paper
• The 1, 2-ethylenediamine SQ109 protects against tuberculosis by promoting M1 macrophage polarization through the p38 MAPK pathway

  2022cites this paper
• Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis

  2022cites this paper
• High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance

  2022influential citation
• Tuberculosis Diagnostics, a journey from the past Experiences to the Future Directions, Review

  2022cites this paper
• Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis

  2022cites this paper
• A Hydrazine–Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3

  2022cites this paper
• The filarial and the antibiotics: Single or combination therapy using antibiotics for filariasis

  2022cites this paper
• MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

  2022cites this paper
• Novel tuberculosis combination regimens of two and three-months therapy duration

  2022cites this paper
• Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis

  2021cites this paper
• Advances in Host-Directed Therapies Against Tuberculosis

  2021cites this paper
• Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

  2021cites this paper
• Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii

  2021cites this paper
• Has the Time Come for Systematic Therapeutic Drug Monitoring of First-Line and WHO Group A Antituberculosis Drugs?

  2021cites this paper
• Effects of Increasing Concentrations of Rifampicin on Different Mycobacterium tuberculosis Lineages in a Whole-Blood Bactericidal Activity Assay

  2021cites this paper
• The pipeline of new molecules and regimens against drug-resistant tuberculosis

  2021cites this paper
• High‐dose rifampicin for the treatment of tuberculous meningitis: a meta‐analysis of randomized controlled trials

  2021cites this paper
• Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis

  2021cites this paper
• Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary <italic toggle='yes'>Mycobacterium kansasii</italic>

  2021cites this paper
• Treatment effect measures for culture conversion endpoints in phase IIb tuberculosis treatment trials.

  2021cites this paper
• Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.

  2021cites this paper
• Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness

  2021cites this paper
• Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review

  2021cites this paper
• Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]

  2021cites this paper
• Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis

  2021cites this paper
• Chemical–genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy

  2021cites this paper
• Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment

  2021influential citation
• Standard VS high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis.

  2021cites this paper
• The Treatment of Tuberculosis

  2021cites this paper
• Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial

  2021cites this paper
• A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

  2021cites this paper
• A Review of Using Mathematical Modeling to Improve Our Understanding of Bacteriophage, Bacteria, and Eukaryotic Interactions

  2021cites this paper
• Application of marine natural products in drug research.

  2021cites this paper
• Novel treatments in multidrug-resistant tuberculosis.

  2021cites this paper
• Lipid Transporters: From Bacteria, Protozoa, Fungi and Plants, to Mice and Men

  2021cites this paper
• Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV

  2021cites this paper
• Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

  2021cites this paper
• Miliary tuberculosis in a paediatric patient with psoriasis

  2021cites this paper
• Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

  2021cites this paper
• Phase 2b Open-label Randomized Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of N-acetylcysteine in Reducing Adverse Drug Reactions among Adults Treated for Multidrug-resistant Tuberculosis in Tanzania. (Trial Acronym NAC Trial).

  2021cites this paper
• Hepatic Safety of High-Dose Rifampicin for Tuberculosis Treatment in TB/HIV Co-infected Patients: A Randomized Clinical Trial

  2021cites this paper
• Central nervous system tuberculosis.

  2020cites this paper
• Clinical Trials of TB-HDT Candidates

  2020cites this paper
• Tuberculosis diagnostics: overcoming ancient challenges with modern solutions

  2020cites this paper
• Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

  2020cites this paper
• Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis

  2020cites this paper
• Modern Anti-Tuberculosis Drugs and Their Classification. Part I: First-Line Drugs

  2020cites this paper
• A review of recent advances in anti-tubercular drug development.

  2020cites this paper
• Disseminated Mycobacterium bovis Infection Complicated by Meningitis and Stroke: A Case Report

  2020cites this paper
• Shortened Tuberculosis Treatment for People with HIV in South Africa: A Model-based Evaluation and Cost-effectiveness Analysis.

  2020cites this paper
• Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

  2020cites this paper
• Current advances in the clinical development of anti-tubercular agents.

  2020cites this paper
• Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis

  2020cites this paper
• Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.

  2020cites this paper
• Management of falsepositive rifampicin resistant Xpert MTB/RIF - Authors' reply.

  2020cites this paper
• Treatment guidelines for tuberculosis and tuberculous meningitis

  2020cites this paper
• TB Elimination Requires Discovery and Development of Transformational Agents

  2020cites this paper
• Evaluation of pharmacokinetic‐pharmacodynamic relationships and selection of drug combinations for tuberculosis

  2020cites this paper